An observational study in Cancer, Early Detection of Cancer and Minimal Residual Disease, sponsored by Caris Science, Inc.. Recruiting at 38 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Caris Science, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Neoplasm, Residual with a site in United States — 26 open to participants now, 46 under way, 1 of them phase 3. Neoplasm, Residual · United States.
Among the 87 studies in Neoplasm, Residual with a site in United States, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2010, is one of 13 observational ones, reaches primary completion later than 37 of the 45 other live ones, and was the 9th registered.
294 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.
Browse Neoplasm, Residual studies →26 of the 87 studies in Neoplasm, Residual with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Puerto Rico
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
Jacqueline Garcia, MD · Sites in United States
Ages 18+
Tempus AI · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Neoplasm, Residual studies recruiting now, 59 (63%) set no upper age limit and 24 (26%) stop at 75 or younger; 18 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 47 · Phase 3 2 · Phase 4 1
First in 2004; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100,000 is above the median of 107 across 88 observational studies indexed under Neoplasm, Residual.
Median enrollment 37 across the 74 interventional studies, 150 across the 13 observational. Of the 34 that completed or were terminated, 17 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 87 have an industry lead sponsor. The 10 most frequent:
Caris Science, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Caris Science, Inc. has 1 study filed under Neoplasm, Residual — fewer than ten, so there is no comparison to draw.
12 of the studies in Neoplasm, Residual with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT05219734Invitae CorporationMRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment | 2026-12 |
| NCT04434040Dana-Farber Cancer InstituteAtezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | 2026-12-30 |
| NCT03945721Massachusetts General HospitalA Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients | 2026-12-31 |
| NCT06663787Nagoya City UniversityPersonalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 87 studies in Neoplasm, Residual with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients.
The Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time.
The Caris Biorepository is an effort toward defining the future of medicine incorporating the discoveries of the genomic era by providing physicians, researchers and scientists access to quality human specimens and data aimed at improving human health and fighting disease. This will be accomplished through acquiring and sharing valuable biospecimen information and clinical outcomes in a collaborative, secure environment. The Caris Biorepository will bridge the gap and correlate human specimens with clinical and specimen data valuable to multiple and varying entities interested in advancing science with precision medicine by targeting disease treatments.
The objective of this project is to develop and implement a state-of-the-science Biorepository that ensures molecular integrity and clinical relevance of human biospecimens used in research and clinical medicine. The Caris Biorepository will also provide vital biospecimens and data to internal researchers and external research collaborators such as government, academia and industry collaborators for the use of drug development discoveries, clinically relevant research trials, publications and posters, and the implementation of future healthcare policies. This project may also impact characterization of trends in practice patterns and their relation to patient outcomes as well as the economic implications of differing evaluation, treatment and management paradigms.
294 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.
This study's planned enrollment of 100,000 is above the median of 107 across 88 observational studies indexed under Neoplasm, Residual.
Browse Neoplasm, Residual studies →Caris Science, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Compared within Neoplasm, Residual, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Healthy volunteers as well as those with a known disease state or condition
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Donor samples reflective of a "normal" non-disease state
Donor samples derived from treatment naïve patients with newly diagnosed solid tumors.
Donor samples reflective of a population at increased risk for developing cancer.
Donor samples derived from individuals with advanced stage cancer.
Donor samples obtained from individuals with a history of malignancy who are currently free of active disease
Develop biorepository that ensures molecular integrity and clinical relevance of quality human biospecimens and associated clinical data.
Retention of biospecimen samples with DNA
Time frame: 35 years
Implement release of specimens from biorepository for testing
Research for the purposes of cancer laboratory diagnostic tests.
Time frame: 35 years
Laboratory testing
DNA and RNA microarray
Time frame: 35 years
Laboratory testing
Immunohistochemistry
Time frame: 35 years
Laboratory testing
Gene and protein expression, proteomics and matabolomics
Time frame: 35 years
Laboratory testing
Mutation analysis
Time frame: 35 years
Laboratory testing
Experiemental lab testing for development of new diagnostic technology
Time frame: 35 years
Laboratory testing
Microvesicle discovery, characterization and validation.
Time frame: 35 years
The record gives a start of Nov 2010, a primary completion of Nov 2030 and a completion of Nov 2035. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Caris Science, Inc.